|
2024
|
Invention
|
Psma-targeted radiopharmaceuticals for treatment of cancer. A treatment for patients having cance... |
|
|
Invention
|
Psma-targeted radiopharmaceuticals for treatment of cancer. Pharmaceutical compositions comprisin... |
|
|
Invention
|
Use of radiopharmaceuticals for treatment of cancer. Disclosed are methods of co-administration o... |
|
|
Invention
|
Claudin 18.2-targeted compounds and uses thereof. Compounds, e.g., radioimmunoconjugates includin... |
|
|
Invention
|
Psma-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy. Combina... |
|
|
Invention
|
Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof. Radiopharmaceutical c... |
|
|
Invention
|
2,4-dihyroxy-5-isopropylphenyl derivatives and pharmaceutical compositions thereof effective as e... |
|
|
Invention
|
Steap2–targeted compounds and use thereof. The present disclosure provides compounds or pharmaceu... |
|
2023
|
Invention
|
Combination comprising a neurotensin receptor binding compound and napoli.
The present invention... |
|
|
Invention
|
Combination comprising a neurotensin receptor binding compound and folfirinox.
The present inven... |
|
|
Invention
|
Combination comprising a neurotensin receptor binding compound and napox.
The present invention ... |
|
|
Invention
|
Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel.
... |
|
|
Invention
|
2,6-dichlorophenyl ester compounds and use thereof.
The present disclosure relates to 2,6-dichlo... |
|
|
Invention
|
Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof. Conjugates comprising... |
|
|
Invention
|
Methods of dosing therapeutic agents. MMmaxtranstranstranstrans to reach a desired clinical endpo... |
|
|
Invention
|
Gucy2c-targeted radiopharmaceuticals and use thereof. Compounds comprising a monocyclic peptide t... |
|
|
Invention
|
Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy.
Metho... |
|
|
Invention
|
Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy.
Combination the... |
|
|
Invention
|
Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy.
Methods for tr... |
|
|
Invention
|
Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy. Method... |
|
|
Invention
|
Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy. Methods for tre... |
|
|
Invention
|
Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy. Combination ther... |
|
2022
|
Invention
|
Egfr-cmet–targeted compounds and uses thereof. Compounds, e.g., radioimmunoconjugates, including ... |
|
|
Invention
|
Methods of treating cancer. Methods of treatment for conditions, e.g., cancer, using a cold IGF-1... |
|
|
Invention
|
Claudin 18.2-binding antibodies and fragments thereof. Disclosed herein are antibodies and antibo... |
|
|
Invention
|
Egfrviii-targeted compounds and uses thereof. Compounds, e.g., radioimmunoconjuguates including a... |
|
|
Invention
|
Combination comprising a neurotensin receptor binding compound and folfirinox. The present invent... |
|
|
Invention
|
Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel. T... |
|
|
Invention
|
Combination comprising a neurotensin receptor binding compound and napoli. The present invention ... |
|
|
Invention
|
Combination comprising a neurotensin receptor binding compound and napox. The present invention r... |
|
|
Invention
|
Radioimmunoconjugates and checkpoint inhibitor combination therapy.
Combination therapies compri... |
|
|
Invention
|
Radioimmunoconjugates and checkpoint inhibitor combination therapy. Combination therapies compris... |
|
|
Invention
|
2,6-dichlorophenyl ester compounds and use thereof. The present disclosure relates to 2,6-dichlor... |
|
|
Invention
|
Methods for treatment of cancers.
The present disclosure relates to methods of treating a subjec... |
|
|
Invention
|
Methods for treatment of cancers. The present disclosure relates to methods of treating a subject... |
|
|
Invention
|
Endosialin-binding antibody.
The present disclosure relates to the generation of an antibody tha... |
|
|
Invention
|
Methods of treating cancer.
Methods of treatment for conditions, e.g., cancer, using a cold FGFR... |
|
|
Invention
|
Use of a cold fgfr3-targeting molecule and a fgfr3 targeting radioimmunoconjugate for treating ca... |
|
2021
|
G/S
|
Bifunctional chelate material to be used in drug discovery, pharmaceutical development and clinic... |
|
|
G/S
|
Biopharmaceuticals for the treatment of cancer and other diseases consisting of proteins linked t... |
|
|
Invention
|
Tem-1-targeted radioimmunoconjugates and uses thereof. Radioimmunoconjugates including a chelatin... |
|
|
Invention
|
Fgfr3-targeted radioimmunoconjugates and uses thereof.
Radioimmunoconjugates including a chelati... |
|
|
Invention
|
Fgfr3-targeted radioimmunoconjugates and uses thereof. e.g.e.g., cancer, using such pharmaceutica... |
|
|
Invention
|
Sustained immunotherapy.
Methods of inducing CD8+ T cell infiltration into a tumor in a patient ... |
|
|
Invention
|
Macrocyclic chelates and uses thereof.
The present disclosure relates to macrocyclic chelates in... |
|
2020
|
Invention
|
Hsp90-binding conjugates and formulations thereof.
Conjugates of an active agent attached to a t... |
|
2019
|
Invention
|
Radioimmunoconjugates and dna damage and repair inhibitor combination therapy.
Combination thera... |
|
|
Invention
|
Actinium-225 and checkpoint inhibitor combination therapy. Combination therapies comprising admin... |
|
|
G/S
|
Biopharmaceuticals for the treatment of cancer and other
diseases consisting of proteins linked ... |
|
2018
|
G/S
|
Biopharmaceuticals for the treatment of cancer and other diseases consisting of antibodies linked... |
